Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Otorhinolaryngology

Show all topics

DOI

10.1016/s0140-6736(18)32752-1

License

CC-BY

Other Formats

PDF